Effect of Age on the Hemostatic Function in Patients with Degenerative Diseases of the Large Joints by Igor L. Shlykov, PhD¹, ScD¹ et al.
INTERNATIONAL 
JOURNAL                
OF BIOMEDICINE
International Journal of BioMedicine 3(2) (2013) 90-93
CLINICAL RESEARCH
Effect of Age on the Hemostatic Function in Patients with Degenerative Diseases of the 
Large Joints
Irina P. Antropova, PhD¹, Boris G. Yushkov, PhD, ScD², Igor L. Shlykov, PhD, ScD¹
¹Ural Research Institute of Traumatology and Orthopedics named after V. D. Chaklin
²Institute of Immunology and Physiology Ural Branch of RAS   
3Ural Federal University named after the first President of Russia B. N. Yeltsin
Yekaterinburg, Russian Federation
Abstract
Background: Aging is associated with an increased hypercoagulable state. Degenerative diseases of the large joints are also 
accompanied by increased coagulation activity. We investigated the effect of age on the hemostatic function in patients with osteoarthritis.
Material and Methods: The study included 192 patients with osteoarthritis admitted to the clinic for primary hip or knee arthroplasty. 
The patients were categorized into 5 age groups: the age group under 40 years, the 41-to-50-year age group, the 51-to-60-year age group, 
the 61-to-70-year age group, and the age group over 70 years. The general blood clotting tests, platelet number, fibrinogen, antithrombin, 
protein C, TAT, D-dimer, vonWillebrand factor (vWF), PAI-1, ß-thromboglobulin were determined.
Results: Among patients with osteoarthritis, the antithrombin III level significantly decreased by the age of 50; however, above 
the age of 60 there was a distinct decrease in platelet count, and over the age of 70 the activity of the extrinsic coagulation pathway and 
the plasminogen level dropped significantly. TAT and D-dimer levels were elevated in most of the patients.
Conclusion: The decrease in platelet count coupled with the activity of the extrinsic coagulation pathway in elderly osteoarthritic 
patients may increase blood loss during total arthroplasty; also, the drop in the anticoagulant and fibrinolytic potential may play a 
negative role in strengthening the prothrombotic state during the postoperative period.
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Introduction
Advanced age is associated with changes in the hemostatic 
system [1,2]. The activity of coagulation enzymes is increased 
[3], the endothelial dysfunction is intensified [4], in particular the 
synthesis of prostacyclins and the antiaggregatory activity of the 
vessel wall get reduced with age [5]. Aging is associated with the 
increased binding of fibrinogen to the platelet receptor αIIbβ [6] 
and the intensified expression of platelet P-selectin [7].
The  activation  markers  of  coagulation  and  fibrinolysis 
are positively correlated with age [8,9]. However, the markers 
of hemostasis are known to increase in various pathological 
conditions; the increased activity of coagulation and fibrinolysis 
is especially observed in osteoarthritic patients before hip and 
knee arthroplasty [10,11]. Surgical interventions in Orthopedics 
are associated with the increased risk of thromboembolic 
complications [11]. In this context, a study of the effect of age on 
the functioning of the hemostatic system in patients with severe 
degenerative joint diseases generates great interest. 
Material and Methods
The investigation of hemostasis was conducted in 192 
osteoarthritic patients admitted to the clinic for primary hip 
or knee arthroplasty. The patients were categorized into 5 age 
groups: the age group under 40 years included 21 patients (12 men 
and 9 women), the 41-to-50-year age group included 50 patients 
(21 men and 29 women), the 51-to-60-year age group included 
62 patients (27 men and 35 women), the 61-to-70-year age group 
included 46 patients (17 men and 29 women), and the age group 
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over 70 years included 13 patients (8 men and 5 women). 
Venous blood was collected into a test tube to which was 
added 3.8% sodium citrate solution in 9:1 ratio. The parameters 
of plasma hemostasis were investigated in platelet-poor plasma 
(PPP), which was obtained by centrifuging the blood for 15 min 
at 3000 rev/min. Platelet counts were recorded in the EDTA 
stabilized blood using the hematology analyzer Cell-Dyn-1700. 
To evaluate the coagulation system, activated partial 
thromboplastin time (APTT), prothrombin time (PT), and 
fibrinogen concentration based on the Clauss clotting technique 
on the CA-50 coagulometer (Sysmex) were determined using 
commercial kits from “Diagnostica Stago” and “Dade Behring”. 
The thrombin formation activity was determined by the 
quantity  of  complexes  “thrombin  –  antithrombin”  (TAT)  and 
their concentrations were examined employing the enzyme-
linked immunosorbent assay (ELISA), using Enzygnost TAT kits 
(“Dade Behring”). 
D-dimer as a marker of fibrinolysis and fibrin formation 
was measured by the ELISA reagent Asserachrom D-dimer 
(“Diagnostica Stago”). The fibrinolysis system was also assessed 
by  determining  plasminogen,  using  the  amidolytic  technique 
with kits from “Technology Standard”, and by determining the 
plasminogen activator inhibitor type 1 (PAI-1) using the ELISA 
method with kits from Technozym PAI -1 Actibind ELISA 
(Technoclone). 
The physiological anticoagulant antithrombin III was 
studied using the amidolytic method with kits from “Technology 
Standard”, while protein C, the other physiological anticoagulant, 
was determined by the ELISA method using Asserachrom Protein 
C (from Diagnostica Stago). 
Platelet activation was detected by measuring the 
ß-thromboglobulin using the ELISA reagent Asserachrom ß-TG.   
As a  marker of endothelial damage, the vWF antigen level 
was investigated using the reagent TECHNOZYM®vWF:Ag 
ELISA (Technoclone). 
Clotting tests and determination of antithrombin and 
plasminogen were carried out within 2 hours after blood sampling. 
For ELISA testing the samples were frozen and stored prior to the 
study at -20 º C. 
The values      of the parameters obtained were compared 
against the values     of standard reference [12].
All the data was processed employing the variation 
statistical methods using the software Statistica for Windows 6.0. 
Analysis of the distribution of values     obtained was performed 
using the Kolmogorov – Smirnov test. The Mann-Whitney  test 
and Kruskal-Wallis test were used to compare the differences 
between groups. The mean (m) and standard deviation (SD) were 
calculated.
Results and Discussion
Data obtained from the blood sample studies and the plasma 
of the patients of different ages is listed in Table 1.
Contrary to the studies of Hemmeryckx et al. [4], who 
recorded increased platelet number with age in healthy subjects, 
we found a significant decrease in the platelet number in patients 
over 60 years of age. In the absence of any evidence of active 
consumption of platelets, the reduced platelet counts can be 
explained by the decrease of their generation in patients with 
osteoarthritis. However, we observed a tendency for increased 
platelet secretion of β-thromboglobulin in patients over 40 years 
of age, which is consistent with previously reported data [13].
Analysis of age-related changes of the endothelium in 
patients with degenerative joint diseases revealed a tendency for 
the increased endothelial secretion of vWF. The level of this factor 
was also found to be increased in healthy elderly individuals [3]. 
The level of the factors of the extrinsic coagulation pathway 
remained at a stable level in patients under70 years; however, 
over the age of 70 it gradually declined, resulting in a significant 
prolonged prothrombin time (PT) in Group 5. The factors of the 
internal coagulation pathway, conversely, showed a tendency to 
the increase after 40 years of age, as evidenced by the shortening 
of the APTT, consistent with the data obtained earlier [3,8].
The activity of the formation of TAT complexes increased 
relative to the reference value of the norm in the majority of patients 
studied  and  no  significant  differences  was  observed  between 
the groups when compared with healthy individuals [8]. The 
concentration of the substrate for fibrin in osteoarthritic patients 
also exhibited no association with age, which distinguishes them 
from healthy elderly people [2,13].
The concentration of the natural anticoagulant protein C did 
not reduce with age. However, the antithrombin III level dropped 
greatly by the age of 50, thereafter remaining stable up to 70; 
however, in individuals above 70 years of age, a further drop in 
the antithrombin III level was seen. The data obtained showed 
age-related decrease in the potential of the natural anticoagulants 
in patients with degenerative joint diseases, whereas the healthy 
subjects revealed an increase in the anticoagulant levels which, 
according to Sagripanti et al., balances the increase in the 
coagulation potential [8].
The  main  pro-enzyme  of  the  fibrinolytic  system, 
plasminogen, remains stable up to 70 years of age; however, in 
patients above 70 years of age, a significant decline is observed 
that may limit the ability of the fibrinolytic system.
An increase in the concentration of D-dimer is described 
in healthy aging, which indicates the increased production and 
lysis of fibrin [8]. The elevated levels of the fibrin degradation 
products in relation to the reference standards were detected in 
most of the patients with osteoarthritis; however, the tendency 
for the D-dimer level to increase with age remained unchanged.  
The activity of PAI-1, the primary inhibitor of fibrinolysis, did 
not show any significant dependence on age.
Thus, degenerative diseases of the large joints in elderly 
patients are associated with a significant drop in the anticoagulant 
potential due to the decrease in the antithrombin III level and 
the significant reduction of the fibrinolytic potential due to the 
lower plasminogen levels. The presence of these changes against 
the backdrop of the increased thrombin activity and consequent 
fibrin formation may enhance the prothrombotic state during the 
postoperative period. However, the age-related lowering of the 
platelet count and the extrinsic coagulation pathway activity can 
increase the blood loss during total arthroplasty.
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